Author

Usha Bughani

Observed name: U. Bughani

Observed institutions: Emory University, Biocon (India)

ORCID: 0000-0003-4499-0694

Observed ORCID: 0000-0003-4499-0694

OpenAlex ID: A5064564014

MK2: a novel molecular target for anti-inflammatory therapy

2008 · Senthil Duraisamy, Malini Bajpai, et al. · Expert Opinion on Therapeutic Targets · 77

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab

2017 · Usha Bughani, Arindam Saha, et al. · PLoS ONE · 55

BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Cancer Research · 40

PDF

Molecular targeting of E3 ligases – a therapeutic approach for cancer

2008 · Manikandan Lakshmanan, Usha Bughani, et al. · Expert Opinion on Therapeutic Targets · 22

Chemoprevention of familial adenomatous polyposis by bromo‐noscapine (EM011) in the ApcMin/+ mouse model

2011 · Shiwang Li, Amr M. Ghaleb, et al. · International Journal of Cancer · 12

Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers

2009 · Usha Bughani, Shiwang Li, et al. · Recent Patents on Anti-Infective Drug Discovery · 12

Noscapinoids: a new class of anticancer drugs demand biotechnological intervention.

2010 · H. C. Joshi, A. Salil, et al. · CABI eBooks · 9

Enhanced Soluble Production of Biologically Active Recombinant Human p38 Mitogen-Activated-Protein Kinase (MAPK) in Escherichia coli

2007 · Sunil K. Khattar, Pankaj Gulati, et al. · Protein and Peptide Letters · 6

874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy

2021 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Journal for ImmunoTherapy of Cancer · 3

PDF

Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab

2018 · Usha Bughani, Arindam Saha, et al. · PLoS ONE · 3

PDF

Proteases and Kinases: Attractive Targets for Combating Infectious Diseases

2010 · Mona Arabshahi, Usha Bughani, et al. · BENTHAM SCIENCE PUBLISHERS eBooks · 1

Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2025 · Srinivas Reddy Boreddy, Reshmi Nair, et al.

Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth

2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.

Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth

2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.

Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth

2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.

Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.

Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.

Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth

2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.

Abstract 6339: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition

2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Cancer Research

Abstract 939: Chemoprevention of familial adenomatous polyposis by EM011 in the ApcMin/+ mouse model

2010 · Shiwang Li, Amy M. Ghaleb, et al. · Cancer Research

Works count: 20

Citation count: 240

H-index: 7

I10-index: 6